Tarsus Pharmaceuticals Inc. (TARS) exhibits 45.0% gross margins and -24.1% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into -15.7% operating margin and -24.1% ROIC, outpacing sector cost of capital.
ROIC: -24.1% // GM: 45.0%YoY revenue trajectory of +146.7% paired with -0.61% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +146.7% // FCF YLD: -0.61%Altman Z-Score of 10.19 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 10.19 // F-SCORE: 5/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $74.20 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend -14.6% net margins.
NET MARGIN: -14.6% // D/E: 0.21x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TARS & activate live FRED threshold breach alerts.